NIBR in the News ›
May 5, 2013
LGX818, Novartis Boost Seen in Fast Approvals as Protection Ends
Washington Post with Bloomberg
April 22, 2013
LGX818, Made to Fight Melanoma
Carmen Drahl, Chemical and Engineering News
April 4, 2013
Intermittent treatment with vemurafenib may prevent lethal drug resistance in melanoma
Medical Xpress
Stories ›
First genome-wide screen to modify HTT mutation results developed by NIBR Researchers
Huntington's is a genetic disorder in which nerve cells in certain parts of the brain degenerate due to a buildup of mutant protein encoded by the HTT gene. No cure is available.
Media resources/ Information Center ›
View resources for media, including press releases and background materials.
Read how our research and development direction is changing the practice of medicine. Various white papers, videos and brochures illustrate important initiatives.
Research at NIBR
Our global research efforts begin and end with the patient.
Rankings and awards
Collaborations
Novartis is a global collaborator of choice for biotechnology companies and academic centers.
